Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics.
Quesada S, Penault-Llorca F, Matias-Guiu X, Banerjee S, Barberis M, Coleman RL, Colombo N, DeFazio A, McNeish IA, Nogueira-Rodrigues A, Oaknin A, Pignata S, Pujade-Lauraine É, Rouleau É, Ryška A, Van Der Merwe N, Van Gorp T, Vergote I, Weichert W, Wu X, Ray-Coquard I, Pujol P; expert consensus group. Quesada S, et al. Among authors: pujade lauraine e. Eur J Cancer. 2024 Dec 9;215:115169. doi: 10.1016/j.ejca.2024.115169. Online ahead of print. Eur J Cancer. 2024. PMID: 39693891
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
Boidot R, Blum MGB, Wissler MP, Gottin C, Ruzicka J, Chevrier S, Delhomme TM, Audoux J, Jeanniard A, Just PA, Harter P, Pignata S, González-Martin A, Marth C, Mäenpää J, Colombo N, Vergote I, Fujiwara K, Duforet-Frebourg N, Bertrand D, Philippe N, Ray-Coquard I, Pujade-Lauraine E; PAOLA-1/ ENGOT-ov25 Study Group. Boidot R, et al. Eur J Cancer. 2024 May;202:113978. doi: 10.1016/j.ejca.2024.113978. Epub 2024 Mar 2. Eur J Cancer. 2024. PMID: 38471290
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinieri S, Guerra Alía EM, Polterauer S, Yoshida H, Vergote I, Colombo N, Hietanen S, Largillier R, Canzler U, Gratet A, Marmé F, Favier L, Pujade-Lauraine E, Ray-Coquard I. Sabatier R, et al. Eur J Cancer. 2023 Mar;181:42-52. doi: 10.1016/j.ejca.2022.11.029. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36634389 Free article.
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
Loverix L, Vergote I, Busschaert P, Vanderstichele A, Venken T, Boeckx B, Harter P, Brems H, Van Nieuwenhuysen E, Pignata S, Baert T, Gonzalez-Martin A, Han S, Marth C, Neven P, Colombo N, Berteloot P, Mäenpää J, Olbrecht S, Laga T, Sablon E, Ray-Coquard I, Pujade-Lauraine E, Lambrechts D, Van Gorp T. Loverix L, et al. Eur J Cancer. 2023 Jul;188:131-139. doi: 10.1016/j.ejca.2023.04.020. Epub 2023 Apr 27. Eur J Cancer. 2023. PMID: 37245441
PARP Inhibitors in Ovarian Cancer. Reply.
Ray-Coquard I, Pérol D, Pujade-Lauraine E. Ray-Coquard I, et al. N Engl J Med. 2020 Apr 16;382(16):1574-1575. doi: 10.1056/NEJMc2000644. N Engl J Med. 2020. PMID: 32294365 No abstract available.
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, Pujade-Lauraine E. Tjokrowidjaja A, et al. Eur J Cancer. 2020 Nov;139:59-67. doi: 10.1016/j.ejca.2020.08.021. Epub 2020 Sep 23. Eur J Cancer. 2020. PMID: 32977221 Clinical Trial.
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I. Pujade-Lauraine E, et al. JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258. JCO Precis Oncol. 2023. PMID: 36716415 Free PMC article. Clinical Trial.
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I. Callens C, et al. J Natl Cancer Inst. 2021 Jul 1;113(7):917-923. doi: 10.1093/jnci/djaa193. J Natl Cancer Inst. 2021. PMID: 33372675 Free PMC article. Clinical Trial.
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL; Gynecologic Cancer Intergroup Meta-Analysis Committee. Lee CK, et al. Cancer. 2021 Jul 15;127(14):2432-2441. doi: 10.1002/cncr.33517. Epub 2021 Mar 19. Cancer. 2021. PMID: 33740262 Free article.
268 results